Immatics Provides Update on IMA204 ACTengine® Cell Therapy Program Targeting the Tumor Microenvironment
10 sept. 2020 07h00 HE
|
https://immatics.com/
Tuebingen, Germany and Houston, Texas, Sept. 10, 2020 (GLOBE NEWSWIRE) -- IMA204 ACTengine® cell therapy program directed at novel tumor target COL6A3 exon 6 prevalently expressed at high copy...
Immatics veröffentlicht Ergebnisse des zweiten Quartals 2020 sowie Informationen zur Geschäftsentwicklung
03 sept. 2020 07h00 HE
|
Immatics N.V.
Tübingen, Deutschland und Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Abschluss der Fusion mit ARYA Life Science Acquisition Corp. sowie anschließende Börsennotierung an der NASDAQ im...
Immatics Announces Second Quarter 2020 Financial Results and Business Update
03 sept. 2020 07h00 HE
|
https://immatics.com/
Tuebingen, Germany and Houston, TX, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Completed merger with ARYA Life Science Acquisition Corp. and subsequent NASDAQ listing with proceeds from the transaction...
Immatics weitet klinisches Studienprogramm für adoptive Zelltherapien auf Europa aus
18 août 2020 07h00 HE
|
Immatics N.V.
Tübingen, Deutschland und Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Der erste Patient in Deutschland wurde im Rahmen der Immatics‘ ACTengine® IMA202-101 Studie behandeltDie deutsche...
Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs
18 août 2020 07h00 HE
|
https://immatics.com/
Tuebingen, Germany and Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trialGerman regulatory agency,...
Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
06 août 2020 07h00 HE
|
https://immatics.com/
Houston, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP...
Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ
09 juil. 2020 07h00 HE
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, July 09, 2020 (GLOBE NEWSWIRE) -- Houston, Texas and Tuebingen, Germany, July 9, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage...
Immatics schließt Fusion mit Arya ab und gibt US-Börsennotierung an der NASDAQ bekannt
02 juil. 2020 07h00 HE
|
Immatics N.V.
Houston, Texas und Tübingen, Deutschland, July 02, 2020 (GLOBE NEWSWIRE) -- Die Fusion mit Arya Sciences Acquisition Corporation, eine von Perceptive Advisors gegründete „SPAC“, wurde am 1....
Immatics Announces Completion of Business Combination and Listing on NASDAQ
02 juil. 2020 07h00 HE
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, July 02, 2020 (GLOBE NEWSWIRE) -- The business combination transaction with Arya Sciences Acquisition Corporation, a special purpose acquisition company...